HGBL With MYC and BCL2 and/or BCL6 Rearrangements
2 clinical trials · Condition
◉ Watch HGBL With MYC and BCL2 and/or BCL6 Rearrangements
| Record | Firm | Date |
|---|---|---|
| Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma (NCT06830031) | Shanghai Exuma Biotechnology Ltd. | 2025-03-19 |
| SynKIR-310 for Relapsed/Refractory B-NHL (NCT06544265) | Verismo Therapeutics | 2024-11-01 |
Track HGBL With MYC and BCL2 and/or BCL6 Rearrangements automatically
Every clearance here is in the API, with alerts when new ones post.